Clinical Trials Browser

Phase 1/2 × Pancreatic Neoplasms × durvalumab × Clear all

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05927142 2025-02-25

DURIPANC

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1/2 Completed

213 enrolled 42 charts

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT02311361 2021-04-20

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1/2 Completed

65 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms